DK1203770T3 - Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af hyperplasi og andre sygdomme - Google Patents

Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af hyperplasi og andre sygdomme

Info

Publication number
DK1203770T3
DK1203770T3 DK02002073T DK02002073T DK1203770T3 DK 1203770 T3 DK1203770 T3 DK 1203770T3 DK 02002073 T DK02002073 T DK 02002073T DK 02002073 T DK02002073 T DK 02002073T DK 1203770 T3 DK1203770 T3 DK 1203770T3
Authority
DK
Denmark
Prior art keywords
ones
hyperplasia
pyran
dihydropyran
diseases
Prior art date
Application number
DK02002073T
Other languages
Danish (da)
English (en)
Inventor
Suvit Thaisrivongs
Chih-Ping Yang
Joseph Walter Strohbach
Stephen Ronald Turner
Donna Lee Romero
Louis L Skaletzki
Paul Adrian Aristoff
Ronald B Gammill
Paul D Johnson
Harvey Irving Skulnick
Richard C Piper
Ruben A Tommasi
Qingwei Zhang
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Application granted granted Critical
Publication of DK1203770T3 publication Critical patent/DK1203770T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)
DK02002073T 1992-11-13 1993-11-09 Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af hyperplasi og andre sygdomme DK1203770T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US97534392A 1992-11-13 1992-11-13
US9087693A 1993-07-13 1993-07-13
US13064193A 1993-10-01 1993-10-01
PCT/US1993/010645 WO1994011361A1 (en) 1992-11-13 1993-11-09 Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hiv and other retroviruses
EP94900546A EP0668860B1 (de) 1992-11-13 1993-11-09 Pyran-2-onen und 5,6-dihydropyran-2-onen verwendbar für die behandlung von hiv und anderen tetroviren

Publications (1)

Publication Number Publication Date
DK1203770T3 true DK1203770T3 (da) 2005-05-23

Family

ID=27376682

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02002073T DK1203770T3 (da) 1992-11-13 1993-11-09 Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af hyperplasi og andre sygdomme
DK94900546T DK0668860T3 (da) 1992-11-13 1993-11-09 Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af HIV og andre retroviruser

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94900546T DK0668860T3 (da) 1992-11-13 1993-11-09 Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af HIV og andre retroviruser

Country Status (26)

Country Link
EP (2) EP0668860B1 (de)
JP (1) JP3583127B2 (de)
KR (1) KR100314975B1 (de)
CN (1) CN1040321C (de)
AT (2) ATE290531T1 (de)
AU (1) AU687368B2 (de)
BR (1) BR9307451A (de)
CA (1) CA2145661C (de)
CZ (1) CZ291853B6 (de)
DE (2) DE69333771T2 (de)
DK (2) DK1203770T3 (de)
ES (2) ES2237624T3 (de)
FI (1) FI120399B (de)
GE (1) GEP20094660B (de)
HU (1) HU228126B1 (de)
IL (1) IL107556A (de)
LV (1) LV13088B (de)
MY (1) MY119031A (de)
NO (1) NO319914B1 (de)
NZ (1) NZ258013A (de)
PL (1) PL178653B1 (de)
PT (2) PT1203770E (de)
RU (1) RU2134691C1 (de)
SK (1) SK285001B6 (de)
WO (1) WO1994011361A1 (de)
ZA (1) ZA938019B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09502713A (ja) * 1993-09-17 1997-03-18 ジ・アップジョン・カンパニー Ｈｉｖおよび他のレトロウイルス病を治療するのに有用な置換テトロン酸
US5808062A (en) * 1993-11-19 1998-09-15 Warner-Lambert Company Pyrone derivatives as protease inhibitors and antiviral agents
DE69432056T2 (de) * 1993-11-19 2003-10-09 Parke Davis & Co Pyron derivate als protease inhibitoren und antivirusmitteln
HUT77668A (hu) * 1993-11-19 1998-07-28 Parke, Davis & Company Vírusellenes hatású 5,6-dihidropiron-származékok és hatóanyagként azokat tartalmazó gyógyszerkészítmények
US5840751A (en) * 1993-11-19 1998-11-24 Warner-Lambert Company 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
HUT75225A (en) * 1993-11-19 1997-04-28 Parke Davis & Co 5,6-dihydropyrone derivatives as protease inhibitors and antiviral agents
SK63996A3 (en) * 1993-11-19 1996-11-06 Parke Davis & Co Pyrone derivatives as protease inhibitors and antiviral agents
IL129871A (en) * 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
DK0817786T3 (da) * 1995-03-20 2003-05-26 Upjohn Co Substituerede tetronsyrer, der er nyttige til behandling af HIV og andre retrovira
WO1998000173A2 (en) * 1996-07-03 1998-01-08 Pharmacia & Upjohn Company Targeted drug delivery using sulfonamide derivatives
PL193240B1 (pl) * 1997-09-11 2007-01-31 Upjohn Co Sposób wytwarzania hydroksylaktonu i związki pośrednie stosowane w tym sposobie
AU756965B2 (en) 1998-03-12 2003-01-30 Microbial Chemistry Research Foundation Benzofurylpyrone derivatives
EP1281399A3 (de) * 2001-08-01 2004-02-11 Warner-Lambert Company Hemmer mit doppelter Wirkung auf Wachsester- und Cholesterylestersynthese zur Hemmung der Sebumproduktion
DOP2003000641A (es) * 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
CN102030645A (zh) 2003-10-24 2011-04-27 隆萨股份公司 6,6,6-三卤-3,5-二氧代己酸酯的制备方法
SI2032551T1 (sl) * 2006-06-16 2012-01-31 Pharma Mar Sa Antitumorne dihidropiran-2-on spojine
UA104281C2 (ru) 2007-12-20 2014-01-27 Фарма Мар, С.А. Противоопухолевые аналоги пептидов, способ их получения и фармацевтическая композиция на них основе
DE102008055916A1 (de) 2008-11-05 2010-05-06 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Allylalkoholen und ihre Verwendung
WO2010051883A1 (de) 2008-11-05 2010-05-14 Clariant International Ltd Verfahren zur herstellung von dialkylphosphinsäuren, -estern und -salzen mittels allylalkoholen/acroleinen und ihre verwendung
DE102008055914A1 (de) 2008-11-05 2010-05-06 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acroleinen und ihre Verwendung
DE102008056342A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
DE102008056339A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von mono-aminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
CN102186864A (zh) 2008-11-07 2011-09-14 科莱恩金融(Bvi)有限公司 利用丙烯酸衍生物制备二烷基次膦酸、二烷基次膦酸酯和二烷基次膦酸盐的方法，以及它们的用途
DE102008056341A1 (de) 2008-11-07 2010-05-12 Clariant International Limited Verfahren zur Herstellung von monoaminofunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Acrylnitrilen und ihre Verwendung
CN102171226B (zh) 2008-11-11 2015-02-11 科莱恩金融(Bvi)有限公司 利用烯丙基化合物制备单烯丙基官能化的二烷基次膦酸、其盐或酯的方法以及它们的用途
DE102008060036A1 (de) * 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060035A1 (de) 2008-12-02 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-hydroxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylester einer Carbonsäure und ihre Verwendung
DE102008060535A1 (de) * 2008-12-04 2010-06-10 Clariant International Limited Verfahren zur Herstellung von mono-carboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Vinylether und ihre Verwendung
DE102008063668A1 (de) 2008-12-18 2010-07-01 Clariant International Limited Verfahren zur Herstellung von Alkylphosponsäuren, -estern und -salzen mittels Oxidation von Alkylphosphonigsäuren und ihre Verwendung
DE102008063642A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monocarboxyfunktionalisierten Dialkylphosphinsäuren, -estern und -salzen mittels Alkylenoxiden und ihre Verwendung
WO2010069545A2 (de) 2008-12-18 2010-06-24 Clariant International Ltd Verfahren zur herstellung von ethylendialkylphosphinsäuren, -estern und -salzen mittels acetylen und ihre verwendung
DE102008063627A1 (de) 2008-12-18 2010-06-24 Clariant International Limited Verfahren zur Herstellung von monohydroxyfunktionalisierten Dialkylphosphinsäuren,-estern und -salzen mittels Ethylenoxid und ihre Verwendung
DE102008064012A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Halogenfreie Addukte von Alkylphosphonigsäurederivaten und diesterbildenden Olefinen, halogenfreie Verfahren zu deren Herstellung und ihre Verwendung
DE102008064003A1 (de) 2008-12-19 2010-06-24 Clariant International Limited Verfahren zur Herstellung von mono-funktionalisierten Dialkylphosphinsäuren, -estern und -salzen und ihre Verwendung
WO2011039735A2 (en) * 2009-10-02 2011-04-07 Consiglio Nazionale Delle Ricerche Compounds with ddx3 inhibitory activity and uses thereof
CN102690275A (zh) * 2011-03-25 2012-09-26 中国人民解放军第二军医大学 四氢呋喃并[3,4-c]吡喃酮类化合物及其制备方法和用途
CN103044375B (zh) * 2012-12-02 2015-08-12 大理学院 一种二氢吡喃酮化合物及其制备方法和药物用途
CN114835694A (zh) * 2022-05-25 2022-08-02 中国科学技术大学 一种在水介质中合成手性3，4-二氢-2h-吡喃类化合物的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1276654A (fr) * 1958-10-01 1961-11-24 Nouveaux dérivés de l'hydroxy-4-alpha-2-pyrone
FR1276645A (fr) * 1959-12-28 1961-11-17 Wild Heerbrugg Ag Objectif de microscope
EP0403535A1 (de) * 1988-03-01 1990-12-27 The Upjohn Company Kumarine zur inhibierung von reverser transcriptase beim menschen

Also Published As

Publication number Publication date
ATE290531T1 (de) 2005-03-15
PT668860E (pt) 2003-01-31
AU687368B2 (en) 1998-02-26
CA2145661C (en) 2008-04-01
KR950704290A (ko) 1995-11-17
FI120399B (fi) 2009-10-15
FI952302A0 (fi) 1995-05-11
JP3583127B2 (ja) 2004-10-27
BR9307451A (pt) 1999-08-31
NO951899D0 (no) 1995-05-12
CZ107895A3 (en) 1995-12-13
DK0668860T3 (da) 2003-01-20
MY119031A (en) 2005-03-31
DE69333771D1 (de) 2005-04-14
SK285001B6 (sk) 2006-04-06
WO1994011361A1 (en) 1994-05-26
ZA938019B (en) 1995-04-28
CZ291853B6 (cs) 2003-06-18
NZ258013A (en) 1997-02-24
ES2182837T3 (es) 2003-03-16
NO319914B1 (no) 2005-10-03
CN1090279A (zh) 1994-08-03
HUT71558A (en) 1995-12-28
DE69333771T2 (de) 2006-04-06
EP1203770A1 (de) 2002-05-08
EP1203770B1 (de) 2005-03-09
KR100314975B1 (ko) 2002-02-28
CA2145661A1 (en) 1994-05-26
SK61695A3 (en) 1995-10-11
EP0668860B1 (de) 2002-09-11
ATE223910T1 (de) 2002-09-15
HU228126B1 (en) 2012-12-28
PL178653B1 (pl) 2000-05-31
CN1040321C (zh) 1998-10-21
DE69332292D1 (de) 2002-10-17
DE69332292T2 (de) 2003-05-28
GEP20094660B (en) 2009-03-25
PT1203770E (pt) 2005-05-31
RU95112465A (ru) 1997-03-20
FI952302A (fi) 1995-05-11
AU5549394A (en) 1994-06-08
RU2134691C1 (ru) 1999-08-20
PL308998A1 (en) 1995-09-18
ES2237624T3 (es) 2005-08-01
HU9501411D0 (en) 1995-06-28
EP0668860A1 (de) 1995-08-30
IL107556A0 (en) 1994-02-27
IL107556A (en) 2001-08-08
JPH08503216A (ja) 1996-04-09
NO951899L (no) 1995-07-12
LV13088B (en) 2004-01-20

Similar Documents

Publication Publication Date Title
DK1203770T3 (da) Pyran-2-oner og 5,6-dihydropyran-2-oner, der er nyttige til behandling af hyperplasi og andre sygdomme
LV12316A (lv) 16-aizvietoti 4-azoandrostani ka 5-alfa-reduktazes izozima 1 inhibitori
DE69827286D1 (de) Elektromagnetische bestrahlungstherapie
EA200000220A1 (ru) Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы
CA2163904A1 (en) Use of Indolocarbazole Derivatives to Treat a Pathological Condition of the Prostate
DE69305263T2 (de) Carbonsäurederivate als 5-alpha-Reduktase-Inhibitor
ES2105774T3 (es) Procedimiento de tratamiento de la alopecia androgena con inhibidores de la 5-alfa reductasa.
NO991192D0 (no) Middel for behandling av prostatahypertrofi og prostatakreft
ATE206622T1 (de) Verwendung von bismuth-213 konjugate zur behandlung von mikrometastasen
DE69417925D1 (de) 7-substituierte-4-aza-steroid-derivate als 5-alpha-reductase-hemmer
ATE198274T1 (de) 17 beta-aryl-4-aza-steroidderivate
NO951718D0 (no) Fremgangsmåter og sammensetninger av (+)doksazosin for behandling av godartet hyperplasi og aterosklerose
NO975838L (no) Melatoninagonister for behandling av godartet prostatisk hyperplasi
ZA922010B (en) Improved method of treatment for benign prostatic hyperplasia
ITMI922801A0 (it) Antiandroigeni per la terapia dell'ipertrofia prostatica dell'irsutismo dell'acne e della seborrea e relativi procedimenti di preparazione
BR8906008A (pt) Aparelho para dilatacao da uretra prostatica e processo para tratamento de hiperplasia prostatica benigna
NO892044D0 (no) Fremgangsmaate og anlegg for behandling av borekaks.
UA34374A (uk) Спосіб лікування виразкової хвороби дванадцятипалої кишки